Title
Cognitive Evoked Potentials (P300) in Early Huntington's Disease

Permalink
https://escholarship.org/uc/item/2cg6j92t

Journal
Archives of Neurology, 42(10)

ISSN
0003-9942

Authors
Rosenberg, C
Nudleman, K
Starr, A

Publication Date
1985-01-01

DOI
10.1001/archneur.1985.04060090066016

License
CC BY 4.0

Peer reviewed
Cognitive Evoked Potentials (P300) in Early Huntington's Disease

Carl Rosenberg, MD; Kenneth Nudleman, MD; Arnold Starr, MD, PhD

The P3 component of both auditory- and visual-event-related potentials of 13 patients with Huntington's disease was studied and compared with the P3 component of normal patients. The latencies of the patients' P3 components were compared with the latency-age regression lines generated by the normal population in both modalities. A P3 latency was considered abnormal if it fell above the 2-SE limit for the latency-age regression line. The incidence of normal or abnormal P3 latencies in the two modalities was compared with the results of computed tomography, electroencephalography, and neuropsychological testing. Nine patients had abnormal P3 latencies and ten patients had abnormal visual P3 latencies, with seven having abnormal latencies on both tests and 12 having abnormal latencies on one of the two tests. An abnormal P3 latency in one modality did not imply an abnormal P3 latency in the other. An abnormality of the P3 latency did not correlate with an abnormality in results from computed tomography, electroencephalography, or neuropsychological testing.

SUBJECTS AND METHODS

Subjects

We studied 13 patients with Huntington's disease, including three men and ten women between the ages of 26 and 66 years. The diagnosis was confirmed by clinical examination and family history. The mean duration of symptoms in these patients was 4.8 years (SD, 2.4 years), with a range of one to nine years. Only one of the patients was living in a skilled-care facility and the others were living at home. Six patients were treated with haloperidol (Haldol) at the time of testing, with the maximum dose for any patient being 6 mg/day. One patient was receiving 75 mg/day of chloropromazine (Thorazine). The procedures were explained to all of the patients and informed consent was obtained.

Event-Related Potentials

Event-related potentials were recorded in an "oddball" paradigm in both the auditory and visual modalities. The subject was required to press a button when a rare target stimulus appeared interspersed in a train of irrelevant frequent signals. The P3 component seems to be related to stimulus processing, either through context updating, information content, or uncertainty resolution. The latency of this component is considered to be a measure of the speed of cognition and has been shown to increase with age in patients with dementia of Alzheimer's disease (J. M. Polich, L. Howard, A.S., unpublished data, 1984). The P3 component is an electrophysiological marker in patients with disorders of cognition.

Huntington's disease is a genetically inherited disorder characterized by a gradual deterioration of mental function and chorea. Disturbances of mood, memory, and personality may be the first features of the disease and can predate the appearance of motor signs. This study evaluates the P3 component in patients with Huntington's disease and compares these event-related potential results with clinical evaluation, computed tomography (CT), electroencephalography (EEG), and neuropsychological tests.

Accepted for publication Nov 8, 1984.

From the Department of Neurology, University of California Medical Center at Irvine, Orange.

Reprint requests to Electrodiagnostics Laboratory, Route 38, University of California at Irvine Medical Center, 101 City Dr S, Orange, CA 92665 (Dr Rosenberg).
criteria were not met, the tracings were not included in the results.

The mean latencies of components N1 and P2 were compared with the normal values for the two modalities developed in our laboratory from individuals between the ages of 20 and 80 years (C.R., A.S., L.W. Meyer, unpublished data, 1983). The P3 latency of the patients with Huntington's disease was defined as abnormal if the absolute latency fell above twice the SE of the P3 latency-age regression line of the normal subjects for the same modality.

The results of the P3 measures in both modalities were compared with the results of 16-channel EEG, CT, neuropsychological testing, and the haloperidol medication history.

For each component, a normalized amplitude at F3 and P3 was calculated by defining the ratio of the amplitude at F3 or P3 to F3 or P3. The P3 amplitude at C3 and the normalized amplitudes at F3 and P3 were compared between the patients and the normal subjects.

Ten of the 13 patients were also tested with a pattern-reversal stimulus to evoke sensory visual potentials. Each eye was tested separately with an alternating checkerboard pattern subtending 15° of visual field, with each check covering 50 minutes of arc. A stimulus rate of 1.1/s was used. Potentials were measured at O1, O2, and 5 cm laterally, referenced to Fz. The filter bandpass was from 5 to 100 Hz. The latency of the P100 was measured at O1, and compared with the normative data used in our clinical laboratory, in which the upper limit of the P100 latency is 112 ms (+2.5 SD).

EEG

Ten of the 13 patients had an EEG, performed within one year of this study, that was made according to the guidelines of the American Electroencephalographic Society. Each EEG was classified as "normal," "low voltage," or "abnormal."

CT

Eleven of the 13 patients underwent CT scanning that was enhanced, unenhanced, or both. All of the scans were performed within one year of this study and classified as "normal," "caudate atrophy," "diffuse cortical atrophy," or a combination of caudate and cortical atrophy.

Neuropsychological Evaluation

Ten patients were tested with the Wechsler Adult Intelligence Scale Trails A and Trails B tests within 18 months of this study. One of us (K.N.) recorded a clinical impression of each patient's degree of dementia as "normal" or "impaired." The latter category was subdivided into "mild," "moderate," or "severe."

RESULTS

Event-Related Potentials

The patients performed well on both the auditory and visual tasks. The mean auditory reaction time was 414 ms (SD, 129 ms), with a range of 207 to 644 ms. The mean visual-reaction time was 451 ms (SD, 112 ms) with a range of 207 to 644 ms. There was a mean of six errors on the visual task, with a range of zero to 18 errors. By comparison, the mean auditory reaction time of the control subjects was 243 ms (SD, 60 ms) and their mean visual reaction time was 300 ms (SD, 85 ms), both being faster than those found in the patients. Statistically the differences were insignificant. The control mean number of errors was one in both the auditory and visual tasks.

Figures 1 and 2 show the potentials elicited to the target and nontarget stimuli (both auditory and visual signals) in both a normal subject and a patient. As neither the N1 nor the P2 latencies has a significant correlation with age in normal subjects, the patients' mean latency of these components was compared with the mean latency in normal subjects in both modalities. In the auditory modality the patients' P2 latency was significantly later than normal subjects' (P < .01; 136 vs 165 ms). There was no difference in the N1 latency to both auditory and visual stimuli, nor to the visual P2 latencies (Table).

The latencies of the P3 component to auditory and visual stimuli are plotted in Fig. 3. In the auditory modality, four patients had a normal P3 latency and nine patients had an abnormal P3 latency. In the visual
modality three patients had a normal P3 latency and nine patients had an abnormal P3 latency. One patient's visual P3 latency could not be measured because of excessive eye movement. An abnormal auditory P3 latency did not necessitate an abnormal result on the visual test or vice versa. Thus, of the nine patients with abnormal auditory P3 latencies, seven also had abnormal visual P3 latencies. Likewise, of the nine patients with abnormal visual P3 latencies, five also had abnormal auditory P3 latencies. Only one of the 13 patients had both a normal auditory and visual P3 latency. There were no significant differences in amplitude or normalized amplitudes at any of the scalp locations in either modality between the patients and the control subjects.

EEG

Six patients had normal EEGs, three had abnormal EEGs (diffuse slow activity), and one had a low-voltage EEG. There was no correlation between the P3 latencies and the status of the EEG in either modality.

CT

One patient had a normal CT scan, one patient had cortical atrophy only, five patients had only caudate atrophy, and four patients had atrophy of both the caudate nucleus and the cortex. There were no significant differences between the CT scans of those patients with normal P3 latencies compared with those patients with abnormal latencies.

Neuropsychological Evaluation

The mean full-scale IQ was 89 (SD, 16), with a range of 76 to 117; the mean verbal IQ was 91 (SD, 17), with a range of 71 to 118, and the mean performance IQ was 82 (SD, 18), with a range of 63 to 117. The mean difference between the verbal and performance IQs was 6 (SD, 12), with a range of -15 to 23. All of the patients who were tested had abnormal scores on the Trails A and the Trails B tests. In the clinical assessment of dementia, four patients were classified as normal, four as mildly affected, and five as moderately affected. There were no significant differences between those patients with normal and abnormal P3 latencies in relation to the results of these measures.

Haloperidol

Of the six patients taking haloperidol at the time of this study, two had normal auditory P3 latencies and one had a normal visual P3 latency. Of the remaining six patients (excluding the patient taking chlorpromazine), two had normal auditory P3 latencies and two had normal visual P3 latencies. There was no significant difference between the distribution of normal and abnormal P3 latencies between those patients taking haloperidol and those not taking haloperidol in either modality.

Pattern-Reversal Visual-Evoked Responses

The potentials from the right eye of one patient and from both eyes in another patient could not be interpreted because of movement artifact. In the remaining patients, the P100 latencies from both eyes were normal except in one patient, whose P100 latency from the right eye was prolonged (114 ms). The mean P100 latency from testing the right eye was 98.2 ms (SD, 3.9 ms), with a mean amplitude of 0.79 µV (SD, 0.53 µV). The mean P100 latency from testing the left eye was 97.5 ms (SD, 6.6 ms), with a mean amplitude of 0.71 µV (SD, 0.55 µV).

COMMENT

This study demonstrates a high incidence of abnormal P3 latencies of event-related potentials to auditory and visual stimuli in patients with Huntington's chorea. Nine patients had abnormal auditory P3 latencies and ten patients had abnormal visual P3 latencies. Twelve of the 13 patients had an abnormal latency in one of the two test criteria. The P3 latency did not correlate with the presence of cerebral or caudate atrophy, slowing on the EEG, or abnormalities in neuropsychological testing.

In this study, a P3 latency was abnormal if it fell outside twice the SE of the appropriate latency-age regression-line limits comparable with the 95% confidence limit in a two-tailed test, but when only one end of the distribution curve was used the confidence limit was 97.5%. The determination of normal limits attempts to balance the rate of false-positives and false-negatives. Ninety-five percent confidence limits are routinely used in the clinical pathology.
The adjective “early” is appropriate in our population of patients. The mean duration of symptoms was only 4.8 years, which is small compared with a 12-year life expectancy after the appearance of symptoms. Huntington’s disease is characterized by a progressive deterioration of motor and mental functioning resulting in the inability to perform many of the simplest of daily activities. The patients in our study were, with one exception, all living at home. The one patient who required skilled care was relatively preserved intellectually but had severe motor impairment. The degree of intellectual deterioration in our patient population can be estimated from the results of neuropsychological testing, in particular on the full-scale IQ test. The lowest full-scale IQ measured in our population was 76, just below the lower limit of normal (80). Our patients’ mean score was 89, which is within the normal range.

The P3 latency was abnormal in at least one of the two modalities in 92% of the patients. The rate of abnormality was similar to the rate of abnormality seen in these patients with CT scanning (9/10), and on the Trails A and Trails B tests (8/8). The rate of abnormality of the P3 latency was greater than that seen with EEG (4/10) and on the full-scale Wechsler Adult Intelligence Scale (2/8, with the lower limit of normal being 80). Consideration of the performance and verbal scores separately did not enhance the definition of abnormality.

The pathologic characteristics of Huntington’s disease include diffuse cortical atrophy with wide neuronal loss, especially in the caudate nucleus and the third, fifth and sixth layers of the cerebral cortex. Autopsy studies are generally derived from individuals who died in the later stages of the disease. The variability of symptoms and signs in this disease suggests that the sequence of affected structures can vary from patient to patient and, indeed, account for the delay in cognitive or global loss. Nevertheless, the finding of a normal P100 latency on the visual-evoked potential eliminates a disorder of transmission time along the primary visual pathway as the explanation of the prolonged visual P3 latencies. One can postulate that the processing of various sensory modalities is differentially affected in individuals with Huntington’s disease.

None of the findings of EEG studies or neuropsychological testing are specific for Huntington’s disease, whereas isolated caudate atrophy combined with the clinical examination is diagnostic of the disease. The P3 latency is also a nonspecific measure of dysfunction. A prolongation of P3 latency in patients with dementias of various causes has been described. Moreover, the mean P3 latency of patients with Parkinson’s disease has been shown to be greater than the mean latency of age matched control subjects. There is also evidence that the P3 latency can be “normal” in a significant proportion of patients with dementia. In our study, the probability of detecting an abnormal P3 latency was enhanced by testing two different sensory modalities.

This study was supported in part by National Institutes of Health grant NS11976.

References